Townsquare Media, Vestis, and Ashland: 3 Under-the-Radar Stocks to Watch

Photo of William Temple
By William Temple Published

Quick Read

  • All three companies are turning operational corners after extended periods of weakness, with Townsquare pivoting to digital, Vestis improving execution metrics, and Ashland stabilizing its cash generation and narrowing guidance.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Townsquare Media, Vestis, and Ashland: 3 Under-the-Radar Stocks to Watch

© 24/7 Wall St.

Most investors chase the same megacap names. But sometimes the most interesting setups are hiding in plain sight: a micro-cap media company quietly becoming a digital business, a uniform rental operator working through a real turnaround, and a specialty chemicals company with a much healthier balance sheet. Here are three stocks worth watching, ranked from interesting to most compelling.

#3: Townsquare Media

Townsquare Media (NYSE:TSQ) is a local radio and digital marketing company operating in small and mid-sized U.S. markets, which insulates it somewhat from competition facing big-city broadcasters.

The headline numbers from Q3 2025 look messy. Revenue fell 7.4% year-over-year to $106.76 million, but strip out political advertising, which collapsed 95.4% due to election cycle comparisons, and the real decline was -4.5%. The EPS beat was genuine: $0.05 against a $0.03 estimate.

The real story is the digital pivot. Digital now represents 55% of total net revenue, and the Townsquare Interactive subscription segment delivered segment profit growth of 21.1% year-over-year in Q3. Direct digital advertising revenue grew +7% year-over-year in the same period. Broadcast is still declining but becoming a smaller piece each quarter.

The risks are real. Net leverage sits at 4.74x and shareholders’ equity is negative at -$33.96 million. Cash on hand is thin at $3.2 million. That said, management has been buying. On January 14, CEO Bill Wilson and the full board made a coordinated purchase at $5.41 per share, with Wilson acquiring over 700,000 units in total. The stock trades at $7.17, up 43.45% year-to-date. Analysts carry a consensus target of $13.50, and the trailing P/E is just 6x. The ~10.8% dividend yield is eye-catching but carries leverage risk.

#2: Vestis

Vestis (NYSE:VSTS) rents uniforms and workplace supplies to businesses across the U.S. and Canada. Spun out of Aramark in late 2023, it has had a rough run since, but the trajectory is finally turning.

The turnaround thesis rests on one number: free cash flow jumped to $28.3 million in Q1 FY2026, compared to nearly nothing in the prior year period. Operating cash flow was $37.69 million. Adjusted EBITDA grew sequentially from $64.66 million in Q4 2025 to $70.38 million in Q1 FY2026. Plant productivity improved 7% year-over-year, on-time deliveries were up 3%, and customer complaints fell 12%.

CEO Jim Barber laid out the path clearly: “We have made meaningful progress advancing our operational excellence priorities. During the quarter we saw significant improvements in plant productivity, on-time deliveries and customer satisfaction.” The company is targeting at least $75 million in annual cost savings by end of FY2026.

Challenges remain. Revenue fell 3% year-over-year to $663.39 million and net leverage remains elevated at 4.83x. Business retention at 91.2% is still declining. Analysts lifted their consensus price target roughly 29% after the Q1 FY2026 print, but the stock at $7.53 is still down 31% over the past year. This is a show-me story, not a done deal.

#1: Ashland

Ashland (NYSE:ASH | ASH Price Prediction) makes specialty chemicals used in pharmaceuticals, personal care, and industrial applications. Pricing power and formulation expertise create durable competitive advantages.

The most recent quarter showed a company regaining its footing. Life Sciences revenue grew 4% year-over-year to $139 million, with segment adjusted EBITDA climbing 11% to $31 million. Free cash flow came in at $111 million in Ashland’s seasonally weakest quarter, boosted by a $103 million tax refund from the Nutraceuticals divestiture. Cash on hand stood at $304 million.

CEO Guillermo Novo narrowed FY2026 adjusted EBITDA guidance to $400 million to $420 million and reiterated targets for double-digit-plus adjusted EPS growth. The manufacturing optimization program is expected to deliver roughly $30 million in savings in FY2026 alone from a $90 million total program.

Headwinds exist. Specialty Additives revenue fell 11% and a Calvert City facility outage dragged results by roughly $10 million. Asbestos litigation reserves stand at $372 million. The stock has pulled back sharply, trading at $50.98, down 12.53% year-to-date, well below the analyst consensus target of $68. The forward P/E sits at roughly 13x.

The Bottom Line

All three companies are navigating real operational challenges. Townsquare trades at a low valuation with recent insider purchases and a digital segment growing faster than headline revenue suggests. Vestis is showing improving cash flow metrics and management is executing against a stated cost savings plan. Ashland has a strong balance sheet, a growing Life Sciences segment, narrowed guidance, and a forward P/E of roughly 13x. Its consensus analyst price target stands at $68, compared to its current price of $50.98, down 12.53% year-to-date.

Photo of William Temple
About the Author William Temple →

I write to invest, and I invest to spend more time with nature. Usually all at the same time. I'm a retired equities guy who saw a recession or four, and lives for what comes out of the other side of them.

I cover stocks across the board cause even though I feel like I've seen it all, there's always another way out there to make, and lose money. I want to help you do more of the former, and none of the latter. Making money with friends is my oxygen.

Let's go!

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618